Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00186368 · ClinicalTrials.gov registry record
Microarray Analysis of Gene Expression in Prostate Tissues
A clinical trial, sponsored by Stanford University.
- Completed
- Registry status
- 867
- Enrollment target
NCT00186368: Completed study, sponsored by Stanford University.
NCT00186368 is a clinical trial that has completed, run by Stanford University. The registered enrollment target is 867 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00186368 has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- 867 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate gene expression profiles and biologic features of prostate tissue and how they relate to prostate cancer development and growth.
Primary Outcome
The Tissue Bank will store all "Tissue Bank" consents. The patients will be given a unique identifier by the tissue bank. However, patients will need to be identified to link to clinical data and possible followup (if they have consented) via chart or tumor registries.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 867 participants |
| Start Date | 1999-04-06 |
| Est. Completion | 2009-04-21 |
What the finished NCT00186368 record still lists
NCT00186368 is an observational study that tracks outcomes without assigning an intervention. The registered 867 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT00186368 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00186368 about?
NCT00186368 is a clinical study titled "Microarray Analysis of Gene Expression in Prostate Tissues". The purpose of this study is to investigate gene expression profiles and biologic features of prostate tissue and how they relate to prostate cancer development and growth.
What is the current status of trial NCT00186368?
This trial is currently completed. The enrollment target is 867 participants. The study started on 1999-04-06. Estimated completion is 2009-04-21.
Who is sponsoring clinical trial NCT00186368?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04933552 · 867 participants
Post-Authorization Safety Study for Assessment of Pregnancy Outcomes in Patients Treated With Mayzent
- NCT06077760 · 868 participants · Phase 3
A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)
- NCT06822790 · 869 participants · Phase 3
Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia
- NCT05369052 · 865 participants · Phase 3
Safety and Efficacy Study of Contezolid Acefosamil and Contezolid Compared to Linezolid Administered Intravenously and Orally to Adults With Moderate or Severe Diabetic Foot Infections (DFI)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI